Login Register Cart 0
Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Prognostic Significance of ZP3 in Hepatocellular Carcinoma

Author(s): Yuanjian Bi, Song Jin, Guorong Tang, Dingquan Pan, Xin Song, Xiaonian Zhu* and Shengkui Tan*

Volume 26, Issue 9, 2023

Published on: 03 November, 2022

Page: [1729 - 1736] Pages: 8

DOI: 10.2174/1386207325666221010112601

Price: $65

Open Access Journals Promotions 2
Abstract

Objective: The study aims to explore the prognostic significance of zona pellucida glycoprotein 3 (ZP3) in hepatocellular carcinoma (HCC) tissues.

Methods: The expression of ZP3 protein in HCC tissues was detected by immunohistochemistry (IHC) to study its effects on the clinicopathological characteristics and prognosis of HCC patients. The Cancer Genome Atlas (TCGA) database was used to confirm the expression of ZP3 in HCC tissues, and Gene set enrichment analysis (GSEA) was performed to obtain potential ZP3-related pathways in HCC.

Results: IHC detection found that ZP3 had a high expression in HCC tissues and was associated with cirrhosis and hepatitis B virus infection in HCC patients (p<0.05). TCGA database also showed that ZP3 was up-regulated in HCC tissues. Further survival evaluation confirmed that ZP3 expression caused an impact on the overall survival time and disease-free survival time of HCC patients (p<0.05), implying a potential role in HCC prognosis. GSEA analysis indicated that the 187 differential gene sets were mainly involved in 10 signaling pathways, including 5 up-regulated and 5 down-regulated pathways.

Conclusion: High expression of ZP3 in HCC tissues is found to have an important role in HCC development and prognosis.

Keywords: Hepatocellular carcinoma, zona pellucida glycoprotein 3, prognostic significance, overall survival, disease-free survival, signaling pathways.

« Previous Next »
Graphical Abstract

[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin., 2021, 71(1), 7-33.
[http://dx.doi.org/10.3322/caac.21654] [PMID: 33433946]
[3]
Chen, J.G.; Zhang, S.W. Liver cancer epidemic in China: Past, present and future. Semin. Cancer Biol., 2011, 21(1), 59-69.
[http://dx.doi.org/10.1016/j.semcancer.2010.11.002] [PMID: 21144900]
[4]
Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin., 2015, 65(2), 87-108.
[http://dx.doi.org/10.3322/caac.21262] [PMID: 25651787]
[5]
Bansal, P.; Chakrabarti, K.; Gupta, S.K. Functional activity of human ZP3 primary sperm receptor resides toward its C-terminus. Biol. Reprod., 2009, 81(1), 7-15.
[http://dx.doi.org/10.1095/biolreprod.108.074716] [PMID: 19246320]
[6]
Wassarman, P.M.; Litscher, E.S. Egg’s ZP3 structure speaks volumes. Cell, 2010, 143(3), 337-338.
[http://dx.doi.org/10.1016/j.cell.2010.10.013] [PMID: 21029855]
[7]
Lefièvre, L.; Conner, S.J.; Salpekar, A.; Olufowobi, O.; Ashton, P.; Pavlovic, B.; Lenton, W.; Afnan, M.; Brewis, I.A.; Monk, M.; Hughes, D.C.; Barratt, C.L. Four zona pellucida glycoproteins are expressed in the human. Hum. Reprod., 2004, 19(7), 1580-1586.
[http://dx.doi.org/10.1093/humrep/deh301] [PMID: 15142998]
[8]
Chiu, P.C.N.; Wong, B.S.T.; Chung, M.K.; Lam, K.K.W.; Pang, R.T.K.; Lee, K.F.; Sumitro, S.B.; Gupta, S.K.; Yeung, W.S.B. Effects of native human zona pellucida glycoproteins 3 and 4 on acrosome reaction and zona pellucida binding of human spermatozoa. Biol. Reprod., 2008, 79(5), 869-877.
[http://dx.doi.org/10.1095/biolreprod.108.069344] [PMID: 18667750]
[9]
Gook, D.A.; Edgar, D.H.; Borg, J.; Martic, M. Detection of zona pellucida proteins during human folliculogenesis. Hum. Reprod., 2007, 23(2), 394-402.
[http://dx.doi.org/10.1093/humrep/dem373] [PMID: 18033806]
[10]
Costa, J.; Pereira, R.; Oliveira, J.; Alves, Â.; Marques-Magalhães, Â.; Frutuoso, A.; Leal, C.; Barros, N.; Fernandes, R.; Queiroz Almeida, D.; Barreiro, M.; Barros, A.; Sousa, M.; Sá, R. Structural and molecular analysis of the cancer prostate cell line PC3: Oocyte zona pellucida glycoproteins. Tissue Cell, 2018, 55, 91-106.
[http://dx.doi.org/10.1016/j.tice.2018.11.001] [PMID: 30503065]
[11]
Rahman, N.A.; Bennink, H.J.T.C.; Chrusciel, M.; Sharp, V.; Zimmerman, Y.; Dina, R.; Li, X.; Ellonen, A.; Rivero-Müller, A.; Dilworth, S.; Ghaem-Maghami, S.; Vainio, O.; Huhtaniemi, I. A novel treatment strategy for ovarian cancer based on immunization against zona pellucida protein (ZP) 3. FASEB J., 2012, 26(1), 324-333.
[http://dx.doi.org/10.1096/fj.11-192468] [PMID: 21974931]
[12]
Song, X.; Zhang, S.; Tian, R.; Zheng, C.; Xu, Y.; Wang, T.; Bei, C.; Zhang, H.; He, X.; Zhu, X.; Tan, S. Expression and clinical significance of CMTM1 in hepatocellular carcinoma. Open Med. (Wars.), 2021, 16(1), 217-223.
[http://dx.doi.org/10.1515/med-2021-0221] [PMID: 33585698]
[13]
Chrusciel, M.; Doroszko, M.; Stelmaszewska, J.; Li, X.; Ziecik, A.J.; Coelingh-Bennink, H.J.T.; Huhtaniemi, I.; Rahman, N.A. Transgenic mice expressing inhibin α-subunit promoter (inhα)/Simian Virus 40 T-antigen (Tag) transgene as a model for the therapy of granulosa cell-derived ovarian cancer. Reprod. Biol., 2014, 14(1), 25-31.
[http://dx.doi.org/10.1016/j.repbio.2013.11.005] [PMID: 24607252]
[14]
Jin, J.; Niu, X.; Zou, L.; Li, L.; Li, S.; Han, J.; Zhang, P.; Song, J.; Xiao, F. AFP mRNA level in enriched circulating tumor cells from hepatocellular carcinoma patient blood samples is a pivotal predictive marker for metastasis. Cancer Lett., 2016, 378(1), 33-37.
[http://dx.doi.org/10.1016/j.canlet.2016.04.033] [PMID: 27160647]
[15]
Shuai, S.; Suzuki, H.; Diaz-Navarro, A.; Nadeu, F.; Kumar, S.A.; Gutierrez-Fernandez, A.; Delgado, J.; Pinyol, M.; López-Otín, C.; Puente, X.S.; Taylor, M.D.; Campo, E.; Stein, L.D. The U1 spliceosomal RNA is recurrently mutated in multiple cancers. Nature, 2019, 574(7780), 712-716.
[http://dx.doi.org/10.1038/s41586-019-1651-z] [PMID: 31597163]
[16]
Zhu, A.X.; Chen, D.; He, W.; Kanai, M.; Voi, M.; Chen, L.T.; Daniele, B.; Furuse, J.; Kang, Y.K.; Poon, R.T.P.; Vogel, A.; Chiang, D.Y. Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. J. Hepatol., 2016, 65(2), 296-304.
[http://dx.doi.org/10.1016/j.jhep.2016.04.015] [PMID: 27130844]
[17]
Hu, J.; Wang, Q.; Liu, Y. Research progress on proteasome subunits in regulating occurrence and development of hepatocellular carcinoma. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2021, 50(3), 396-402.
[http://dx.doi.org/10.3724/zdxbyxb-2021-0146] [PMID: 34402263]
[18]
Wang, H.; Xu, F.; Lu, L.; Yang, F.; Huang, X.; Lv, L.; Hu, H.; Jiang, Y. The diagnostic and prognostic significance of small nuclear ribonucleoprotein Sm D1 aberrantly high expression in hepatocellular carcinoma. J. Cancer, 2022, 13(1), 184-201.
[http://dx.doi.org/10.7150/jca.65225] [PMID: 34976182]
[19]
Pascale, R.M.; Joseph, C.; Latte, G.; Evert, M.; Feo, F.; Calvisi, D.F. DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma? DNA Repair (Amst.), 2016, 47, 12-20.
[http://dx.doi.org/10.1016/j.dnarep.2016.10.004] [PMID: 27789167]
[20]
Gomes, A.P.; Ilter, D.; Low, V.; Drapela, S.; Schild, T.; Mullarky, E.; Han, J.; Elia, I.; Broekaert, D.; Rosenzweig, A.; Nagiec, M.; Nunes, J.B.; Schaffer, B.E.; Mutvei, A.P.; Asara, J.M.; Cantley, L.C.; Fendt, S.M.; Blenis, J. Altered propionate metabolism contributes to tumour progression and aggressiveness. Nat. Metab., 2022, 4(4), 435-443.
[http://dx.doi.org/10.1038/s42255-022-00553-5] [PMID: 35361954]
[21]
Malik, A.; Thanekar, U.; Amarachintha, S.; Mourya, R.; Nalluri, S.; Bondoc, A.; Shivakumar, P. “Complimenting the complement”: Mechanistic insights and opportunities for therapeutics in hepatocellular carcinoma. Front. Oncol., 2021, 10, 627701.
[http://dx.doi.org/10.3389/fonc.2020.627701] [PMID: 33718121]
[22]
Yu, Q.; Wu, L.; Ji, J.; Feng, J.; Dai, W.; Li, J.; Wu, J.; Guo, C. Gut microbiota, peroxisome proliferator-activated receptors, and hepatocellular carcinoma. J. Hepatocell. Carcinoma, 2020, 7, 271-288.
[http://dx.doi.org/10.2147/JHC.S277870] [PMID: 33150145]

Rights & Permissions Print Cite
Article Metrics
37
2
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy